Lessons learned from implementing in AI at regulated medical device manufacturer, ResMed. This includes top 5 challenges and ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that ...

BSX carries a Zacks Rank #2 (Buy), while RMD has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 ...

As the United States approaches 2026, key structural shifts in retirement and healthcare financing are poised to affect how ...

ResMed is on a mission to cement the lead it’s built while competitor Philips has been out of the CPAP machine-making game. That process of building out its market share for the long-term has recently ...

ResMed plans to sign a lease for an about 446,500-square-foot building on Collins Road in Greenwood. The company is seeking a nearly $500,000 three-year tax break from the Greenwood City Council.

Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44 th Annual J.P. Morgan Healthcare ...

If you are wondering whether ResMed is still attractive after its strong run, or if the market has already priced in the upside, this article will help you cut through the noise and focus on what the ...

ResMed achieved double-digit revenue and profit growth over the past 9 years, driven by continuous acquisitions and improving operating efficiencies. ResMed's capital efficiencies showed mixed results ...

ResMed (NYSE: RMD), a medical equipment company, has seen an 18% fall in a month, underperforming the broader S&P500 index, up 1%. The recent fall can be attributed to its downbeat Q4 fiscal 2023 ...

ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple ...